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1. INTRODUCTION
Lung cancer is the most common cause of cancer death world-
wide (1). As advanced lung cancer is difficult to cure with surgery
alone, even after complete resection, postoperative adjuvant treat-
ments are recommended. It has been reported that patients with
completely resected stage I,, andA non-small cell lung cancer
(NSCLC) may benefit from postoperative cisplatin (CDDP)-based
chemotherapy (2-5). Although CDDP-based chemotherapy is
considered the standard regimen, severe toxicities are occasion-
ally observed and chemotherapy-related death has been one of the
problems with adjuvant treatments. As an alternative adjuvant
treatment with fewer adverse reactions, oral adjuvant chemother-
apy with uracil - tegafur (UFT) has been evaluated. UFT improved
the overall survival in patients with completely resected early stage
lung adenocarcinoma with only mild adverse reactions in several
randomized controlled studies (6, 7).
S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) is an oral
fluoropyrimidine derivative consisting of tegafur (FT), 5-chloro-2,
4 -dihydroxypyridine (CDHP), and potassium oxonate (Oxo), in a
molar ratio of 1 : 0.4 : 1 (8). FT is a prodrug of 5- fluorouracil (5 -FU)
and CDHP is a reversible competitive inhibitor of dihydropyrimidine
dehydrogenase (DPD), an enzyme involved in the degradation of 5-
FU. The degradation of FT-derived 5-FU is efficiently inhibited by
CDHP, and 5-FU remains in the plasma and tumor tissue longer
and at higher levels than when low-dose 5-FU is continuously in-
fused intravenously. The major toxicities of fluoropyrimidines are
diarrhea and mucositis (9). Oxo is a reversible competitive in-
hibitor of orotate phosphoribosyltransferase, a phosphoenzyme
for 5-FU, and is distributed at high levels in the gastrointestinal
tract after oral administration, resulting in a reduction in the gas-
trointestinal toxicity caused by 5-FU (10).
Considering the points described above, we hypothesized that
adjuvant chemotherapy with S-1 would be more effective in postop-
erative settings than UFT because it is a more potent DPD inhibi-
tor. We conducted a feasibility study of S-1 as postoperative adju-
vant chemotherapy in patients with curatively resected pathologi-
cal stageandA NSCLC.
2. PATIENTS AND METHODS
2.1. Study design
The present study was designed as a multi -center, single-arm,
clinical phasestudy to evaluate the feasibility of S-1 adjuvant
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therapy in patients with completely resected NSCLC. The primary
endpoint was the rate of completing the scheduled adjuvant chemo-
therapy. The secondary endpoints were safety, overall survival and
relapse- free survival. We could not calculate the number of pa-
tients to be enrolled in this study based on statistical analysis be-
cause this study was an exploratory trial. Twenty- four patients with
completely resected NSCLC were enrolled in this study from
November 2007 through December 2010. The present study was
conducted in accordance with the Declaration of Helsinki. The
protocol was approved by the institutional review board at each
institution.
2.2. Patient eligibility
Patient eligibility required compliance with the following criteria :
(1) histologically proven NSCLC, (2) pathological stage-A
(according to the Union for International Cancer Control 6th edi-
tion) after complete resection, (3) no previous treatment except for
surgery, (4) Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) of 0 or 1, (5) age20 and80 years. Patients
also had to have adequate organ function : 3,000 leukocytes
12,000/m3, neutrophil count1,500/m3, thrombocytes100,000/
m3 ; hemoglobin9.0g/dL, aspartate aminotransferase (AST) and
alanine aminotransferase (ALT)2.5×upper limit of normal (ULN),
total bilirubin1.5 mg/dL, creatinine1.5 mg/dL, creatinine
clearance (Ccr) estimated using Cockcroft -Gault’s formula50
mL/min, and PaO260 mmHg. Any patients with a history of drug
hypersensitivity, serious surgical or nonsurgical complications, or
active secondary cancer were excluded. In addition, pregnant or
lactating women were excluded. Written informed consent was
obtained from all patients.
2.3. Treatment schedule
Administration of S-1 was started within 2-6 weeks after sur-
gery. The treatment comprised 9 courses (4-week administra-
tion, 2-week withdrawal) of S-1 (FT, gimeracil, oteracil potassium ;
Taiho Pharmaceutical) at 80-120 mg per day according to body
surface area (BSA) : BSA1.25m2, 80 mg per day ; 1.25 m2
BSA1.5 m2, 100 mg per day ; and 1.5 m2BSA, 120 mg per
day. S-1 was administrated orally twice daily after meals for 4
weeks, and was thereafter withdrawn for 2 weeks. We checked
drug compliance in an interview when patients visited the hospital.
Administration of S-1 was temporarily discontinued if a patient had
any of the following toxicities : leukocyte count2.0×103 cells/mL,
neutrophil count1.0×103 cells/mL, platelet count75×103 cells/
mL, total bilirubin1.5×ULN, ASTs150 IU/L, ALTs100 IU/L,
serum creatinineULN, Ccr50 mL/min, or other non-hema-
tological toxicitiesGrade 2. On restarting administration of S-1,
the dose was reduced from 120 mg to 100 mg per day, or from
100 mg to 80 mg per day. When treatment was restarted within 7
days, the restart was judged to represent the same course after
temporary discontinuation of drug administration. When treat-
ment could not be restarted within 7 days, the course was skipped
and restarted as the next course. Treatment was discontinued
when the patient exhibited disease recurrence, secondary cancer
or adverse reactions that were uncontrollable using dose modifica-
tion or temporary discontinuation of drug administration. Toxici-
ties were assessed according to the National Cancer Institute
Common Toxicity Criteria (NCI-CTCAE) version3.0.
2.4. Statistical analysis
In the present study, P -values and confidence intervals (CI)
were double-sided, and P0.05 was considered to indicate a sig-
nificant difference. The Kaplan-Meier method was used to esti-
mate the time-to-event functions of overall survival and relapse-
free survival. The log-rank test was used to test for possible differ-
ences between estimated time-to-event curves. Univariate and
multivariate survival analyses were performed using the likelihood
ratio test of the stratified Cox proportional hazards model. Overall
survival was defined as the time from the date of the start of treat-
ment to the date of death or last contact. Relapse- free survival
was as the time from the date of the start of treatment to the date of
disease progression or death (whichever occurred first) or the
date of last contact.
3. RESULTS
3.1 Patient characteristics
Table 1 shows the characteristics of the 24 patients enrolled in
the present study. The average age of the patients was 70 years
(range, 49-79 years). Thirteen patients were 70 years old or older.
Lobectomy or pneumonectomy were performed on all patients.
3.2 Drug compliance
Table 2 shows drug compliance in each course and reasons
for the discontinuation of drug administration. The planned 9
courses of S-1 were administered to completion in 8 patients. Five
patients were censored because of disease recurrence, and there-
fore the completion rate was calculated to be 42.1% ; the average
number of accomplished courses was 6.3. Twelve patients com-
pleted more than 70% of the planned courses. Among these 12
patients, 5 required dose reduction (41.7% of 12 patients). Ten pa-
tients discontinued drug administration because of adverse reac-
tions. One patient refused to continue drug administration be-
cause of financial problems.
3.3 Adverse events
Table 3 shows a summary of the adverse reactions. Among the
adverse reactions, Grade 1 or 2 anorexia (58.3%) was the most
frequent, followed by diarrhea (29.2%), and fatigue (25.0%), which
were reasons for the discontinuation of drug administration. Al-
though Grade 3 total bilirubin elevation and pneumonitis were
Table 1. Patient characteristics.
Variables Number of patients Percentage
Sex
Male 16 66.7
Female 8 33.3
Age (years old)
60 3 12.5
60-69 8 33.3
70-79 13 54.2
Type of resection
Lobectomy 21 87.5
Pneumonectomy 3 12.5
Histology
Adenocarcinoma 19 79.2
Squamous cell carcinoma 4 16.7
Adenosquamous cell carcinoma 1 4.2
TNM stage
A 8 33.3
B 6 25.0
A 10 41.7
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observed in one patient out of 24 patients (4.2%) each, no Grade 4
adverse reactions were noted. There were no treatment-related
deaths.
3.4 Survival
Among the 24 patients followed for survival information, 10 had
died and 14 were still alive at the time of analysis. The median
follow-up time was 70 months (range, 9.5 -97.9). At the time of
analysis, the median overall survival was 92.4 months (95% CI, 45.5 -
139.3) (Figure 1). Fourteen patients relapsed, and the median
relapse- free survival was 45.5 months (95% CI 16.1-75.0) at the
time of analysis (Figure 2). Among 14 patients who relapsed, there
were thorax recurrences in 11 patients. There were distant me-
tastases in 3 patients, and metastases of multiple bones, supracla-
vicular lymph nodes, and adrenal glands were each observed in 1
patient. Except for patients who discontinued treatment because of
disease recurrence, overall survival and relapse- free survival were
not significantly different between patients who completed the
planned 9 courses and those who did not ; however, patients who
completed more than 70% of the 9 courses exhibited better overall
survival than those who completed less than 70% (log-ranktest p=
0.038). In the Cox proportional hazards regression model, comple-
tion of more than 70% of the courses was not statistically significant
prognosticators for overall survival (Table 4). The relapse- free sur-
vival rate also tended to improve in patients who completed more
than 70% of the planned courses (p=0.066) (Figure 3).
4. DISCUSSION
The present study was carried out to confirm the feasibility of
adjuvant chemotherapy with S-1 in patients with curatively re-
sected pathological stage andA NSCLC. The completion
Table 2. Drug compliance (each course) (n=24)
Course Number of patients
entering the course
Percentage Reasons for discontinuation
1 24 100
Grade 2 anorexia (patient refusal)
2 23 95.8
Grade 2 anorexia (patient refusal)
Grade 2 fatigue (patient refusal)
Recurrence
Recurrence
3 19 79.2
Grade 3 Pneumonitis
Grade 2 anorexia and weight loss
(patient refusal)
Recurrence
4 16 66.7
Grade 1 fatigue (patient refusal)
5 15 62.5
6 15 62.5
Financial problem (patient refusal)
Grade 2 Vomiting (patient refusal)
Grade 2 Thrombocytopenia and
elevated T -bil (patient refusal)
7 12 50.0
Recurrence
Grade 3 elevated T -bil
8 10 41.7
Recurrence
Grade 2 Weight loss and grade 1
anorexia (patient refusal)
9 8 33.3
Table 3. Adverse reactions (n=24)
Grade Total
(Incidence%)1 2 3 4
Laboratory Findings
Neutropenia 0 1 0 0 4.2
Thrombocytopenia 0 1 0 0 4.2
Elevated AST 6 0 0 0 25.0
Elevated ALT 4 0 0 0 16.7
Elevated T-bil 3 1 1 0 20.8
Gastrointestinal Findings
Dysgeusia 2 0 0 0 8.3
Anorexia 9 5 0 0 58.3
Nausea 3 1 0 0 16.7
Vomiting 2 0 0 0 8.3
Heartburn 2 0 0 0 8.3
Oral mucositis 3 2 0 0 20.8
Diarrhea 5 2 0 0 29.2
Clinical Findings
Pigmantation 8 1 0 0 37.5
Dry dermatitis 1 0 0 0 4.2
Itch sensation 1 0 0 0 4.2
Sense of fatigue 5 1 0 0 25.0
Pneumonitis 0 0 1 0 4.2
Weight loss 1 2 0 0 12.5
Dacryorrhea 2 0 0 0 8.3
Vertigo 1 0 0 0 4.2
Nosebleed 1 0 0 0 4.2
Abbreviations : ALT=alanine aminotransferase ; AST= aspartate amino-
transferase
Figure 1. Overall survival of the 24 patients.
The median overall survival was 92.4 months (95% CI, 45.5 -139.3).
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rate of the scheduled 9 courses of S-1 administration was 42.1%.
The completion rate of more than 70% of the scheduled 9 courses
was 63.2%. No Grade 4 adverse reactions were observed through-
out the 9 courses. Only 2 Grade 3 adverse reactions were encoun-
tered (8.3% of total). There were no significant differences in the
overall survival rate or the relapse- free survival rate between the
treatment completion group and the incompletion group ; how-
ever, the overall survival rate was improved in patients who com-
pleted more than 70% of the scheduled 9 courses.
Adjuvant chemotherapy after curative surgery with the single-
agent S-1 has been proven to improve the overall survival rate in
patients with gastric cancer in a randomized phasetrial (11). In
that study, adjuvant chemotherapy consisted of 8 cycles (4 weeks of
administration and 2 weeks of withdrawal) of S-1 at the same daily
dose as that used in the present study (80-120 mg/body) and the
completion rate was 65.8%, which was higher than that of the sched-
uled 9 courses in the present study. In the previous study, the mean
age of the patients was 60.3 years and only approximately 30% of the
patients were older than 70 years. In the present study, the mean
age was 68.1 years and approximately 50% of the patients were
older than 70 years. Considering this age difference among the
patients in the different studies, the completion rate of the present
Figure 2. Relapse- free survival among 24 patients.
The median relapse - free survival was 45.5 months (95% CI 16.1 -75.0).
Figure 3. Overall survival (OS) (A) and relapse - free -survival (RFS) rates (B).
Except for the patients who discontinued treatment because of disease recurrence, in the over 70% of completed courses group, OS was
improved and the RFS rate also tended to improve compared with the under 70% completed courses group.
Table 4. Cox proportional hazard regression analysis for overall survival
Factor
Univariate Multivariate
Exp(B) 95% confidenceinterval P value Exp(B)
95% confidence
interval P value
Sex
Male versus Female 1.684 0.196-14.437 0.635
Age (years)
70 versus70 8.325 0.937-73.987 0.057 5.646 0.475-67.396 0.170
Histology
Adenocarcinoma versus others 1.526 0.178-13.086 0.700
pStage
versus 3.223 0.589-17.640 0.177 2.796 0.454-17.230 0.268
Completion rate (%)
70 versus70 0.140 0.016-1.212 0.074 0.420 0.031-5.645 0.513
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study was acceptable.
There were few severe adverse events in the present study. Cur-
rently, the standard regimen for adjuvant chemotherapy in postop-
erative patients with stage-A NSCLC is cisplatin doublet. The
LACE Collaborative Group published a meta-analysis of the 5
largest randomized cisplatin-based trials (5). The LACE meta-
analysis demonstrated that both overall survival and disease- free
survival were improved with the administration of cisplatin. How-
ever, there was a significant interaction between chemotherapy
effects and World Health Organization (WHO) performance status
(PS). In the 5 trials, the rate of overall Grade 3 to 4 toxicity was
66%. It is difficult for patients with a poor PS to receive cisplatin-
based chemotherapy because of this high level of toxicity. In the
present study, the rate of Grade 3 toxicity was 8.3% and there
were no Grade 4 toxicities. Adjuvant chemotherapy with S-1 was
performed with few severe adverse events. The most common ad-
verse events were Grade 1 or 2 anorexia (54.2%), which was the
reason for discontinuation of S-1 administration. Gastrointestinal
toxicities, such as oral mucositis and diarrhea, were also frequent ;
thus, the completion rate may improve with supportive therapies
for gastrointestinal toxicity and with a frequent withdrawal sched-
ule of S-1.
There was a significant benefit for the overall survival rate in
patients who completed more than 70% of the scheduled 9courses.
Although there were no significant differences, the relapse- free
survival rate tended to improve in patients who completed more
than 70% of the scheduled 9 courses. In the Adjuvant Chemother-
apy Trial of TS-1 for Gastric Cancer (ACTS-GC) (11), a random-
ized phasestudy of chemotherapy with S-1 after curative sur-
gery in Japanese patients with locally advanced gastric cancer, the
overall survival rate and the relapse- free survival rate in the S-1
group at 5 years were better than in the surgery-only group. In the
same study, patients who completed more than 70% of the planned
courses exhibited better overall survival than those who completed
less than 70%. The same trend was seen in our present study.
Based on ACTS-GC data, adjuvant chemotherapy with S-1 after
curative resection of advanced gastric cancer is considered the
standard regimen. In NSCLC, some feasibility studies of postop-
erative chemotherapy with S-1 have reported, but there has not
been a randomized study to confirm the effectiveness of postopera-
tive adjuvant chemotherapy with S-1. Some phasestudy of adju-
vant chemotherapy with S-1 (12-16) have been reported (Table 5).
In these studies, the treatment comprised 8 courses of S-1 at 80-
120 mg per day. When comparing the 4-week administration and 2-
week withdrawal setting group with the 2-week administration
and 1-week withdrawal setting group, there was no difference in
the completion rate between the 2 groups. However, a high inci-
dence of Grade 3 or 4 adverse events was observed in the 4-week
administration and 2-week withdrawal setting group. We planned
the treatment schedule as 4-week administration, 2-week with-
drawal of S-1 in our present study. There was no difference in the
incidence of severe adverse events ; however, the completion rate
was low. In the feasibility trial for adjuvant chemotherapy with do-
cetaxel plus cisplatin followed by long term administration of S-1
(14), Grade 3 or 4 neutropenia was observed in 78.5% of patients
during the DOC + CDDP treatment. In contrast, Grade 3 or 4 ad-
verse events were seen in 1.8-7.3% of patients during the S-1 treat-
ment. Iwamoto et al. reported a randomized study of adjuvant che-
motherapy with S-1 versus cisplatin + S-1 in completely resected
advanced NSCLC(17). The incidence of adverse events was signifi-
cantly lower among the patients in the S-1 group, and there was no
significant difference in the overall survival rate and relapse- free
survival rate. The results showed that adjuvant therapy with S-1
could be effective without severe adverse effects.
Kato et al. (6) reported that adjuvant chemotherapy with UFT
with the same DPD inhibitor activity as fluoropyrimidine S-1 im-
proved survival among patients with completely resected stage I
lung adenocarcinoma in a randomized trial. Based on these re-
sults, S-1 can be effective as adjuvant chemotherapy in surgically
removed progressive lung cancer because of more potent DPD
inhibition than UFT. 5-FU was previously thought to be inappropri-
ate for lung cancer treatment because the lung contains higher
levels of DPD than other organs, such as the stomach and colon
(13). However, it was reported that lung adenocarcinoma had
higher DPD expression than squamous cell carcinoma, especially
adenocarcinoma in situ (14). Therefore, S-1 may be more effec-
tive in adjuvant therapy for advanced lung cancer than for gastric
cancer.
There are some limitations in this study. First, the number of
patients in this study is not enough to draw definitive conclusions
from the prognostic analysis. Second, we checked drug compli-
ance in an interview, and had no way of verifying whether the pa-
tients were truthful about drug compliance because S-1 therapy
was performed as an ambulatory treatment.
In conclusion, postoperative administration of S-1 may be possi-
ble with few severe adverse events as adjuvant chemotherapy for
patients with curatively resected pathological stage-A NSCLC.
S-1 can be administered orally with few toxicities ; therefore, it ex-
pected to be a promising agent for adjuvant chemotherapy in ad-
vanced lung cancer. Based on this feasibility study, a randomized
trial to evaluate the efficacy of S-1 as adjuvant chemotherapy with
low toxicity for resected advanced NSCLC is required in the future.
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Table 5. Selected phaseclinical trials of adjuvant chemotherapy with S-1 for completely resected NSCLC.
Trial Drug
Dose/ schedule
No. of pts. Completion rate Adverse events(Grade 3, 4)Per day On days Duration Planned courses
Yano (2010)12 S -1 80 -120 mg 1-14 q3wks 8 30 56.7% 6.7%
Tsuchiya (2012)13 S -1 80 -120 mg 1-28 q6wks 8 50 72% 2%-4%
Niho (2013)14 DOC+CDDP
followed by S-1
60 mg/m2
80 mg/m2
40 mg/m2
Day 1
Day 1
1-14
q3-4wks
q3-4wks
q3wks
3
3
6-12 months
129 51.2% 78.5% (DOC+CDDP)
1.8 -7.3% (S-1)
Okumura (2013)15 S -1 80 mg/m2 1-28 q6wks 8 28 50% 14.2%
Maruyama (2014)16 S -1 50 -100 mg 1-14 q3wks 8 25 50% 4%
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